Menu
| TIME | TOPIC |
| 12:00 P.M. – 12:15 P.M. | Welcome and Opening Remarks Introduction of All Members and Roll Call |
| 12:15 P.M. – 12:30 P.M. | HRSA Division of Transplantation Blood Stem Cell Transplantation Program Update |
| 12:30 P.M. – 12:50 P.M. | Blood Stem Cell Transplantation Trends: An Overview |
| 12:50 P.M. – 1:10 P.M. | Haploidentical Transplantation: An Overview |
| 1:10 P.M. – 1:30 P.M. | Mismatched Bone Marrow Transplantation: An Overview |
| 1:30 P.M. – 2:00 P.M. | A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies |
| 2:00 P.M. – 2:15 P.M. | BREAK |
Potential for Utilization of Cord Blood: An Overview
| TIME | TOPIC |
| 2:15 P.M. – 2:40 P.M. | Cord Blood Derived Virus Specific T Cells |
| 2:40 P.M. – 3:05 P.M. | Cord Blood Derived CAR NK Cells |
| 3:05 P.M. – 3:30 P.M. | Cord Blood in Regenerative Medicine |
| 3:30 P.M – 4:15 P.M. | Cord Blood Transplantation: Challenges and Opportunities |
| 4:15 P.M. – 4:40 P.M. | Consideration of Recommendation on Cord Blood |
| 4:40 P.M. – 4:50 P.M. | BREAK |
Other New Developments
| TIME | TOPIC |
| 4:50 P.M. – 5:05 P.M. | CAR- T Cell Immunotherapies |
| 5:05 P.M. – 5:20 P.M. | CCR5 Genotype |
| 5:20 P.M. – 5:35 P.M. | COVID-19: Impact on Blood Stem Cell Transplantation |
| 5:35 P.M. – 5:45 P.M. | New Business |
| 5:45 P.M. – 6:00 P.M. | Public Comment |